Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- 2' (1)
- 2',5'-Oligoadenylate Synthetase (1)
- 5'-Oligoadenylate Synthetase (1)
- Animals (1)
- Animals, Genetically Modified (1)
-
- Anti-Bacterial Agents (1)
- Area Under Curve (1)
- Beta 2-Microglobulin (1)
- Chickens (1)
- Drug Administration Schedule (1)
- Genetically Modified (1)
- Glycosylation (1)
- Half-Life (1)
- Interferon-alpha (1)
- Messenger (1)
- Middle Aged (1)
- Neopterin (1)
- Pharmaceutic Aids (1)
- Povidone (1)
- Protein Kinases (1)
- RNA (1)
- RNA, Messenger (1)
- Recombinant Proteins (1)
- Taurine (1)
- Therapeutic Equivalency (1)
- Thiadiazines (1)
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
The Pharmacokinetics Of Taurolidine Metabolites In Healthy Volunteers., Li Gong, Howard E Greenberg, James L Perhach, Scott A Waldman, Walter K. Kraft
The Pharmacokinetics Of Taurolidine Metabolites In Healthy Volunteers., Li Gong, Howard E Greenberg, James L Perhach, Scott A Waldman, Walter K. Kraft
Department of Pharmacology and Experimental Therapeutics Faculty Papers
Taurolidine is an experimental antibacterial and antiendotoxic compound whose clinical utility as an antitumor agent is being investigated in human clinical trials. Taurolidine in aqueous solution exists in equilibrium with taurultam. Taurultam is subsequently transformed to taurinamide. The pharmacokinetic profiles of these metabolites are not well established. In this study, 18 healthy volunteers were administered 5.0 g of taurolidine in 250 mL of 5% polyvinylpyrrolidone in water over 2, 1, or 0.5 hours by intravenous infusion in a parallel-group design. All subjects noted discomfort at the infusion site, although there were no serious adverse events. t(max) generally occurred at the …
Transgenic Avian-Derived Recombinant Human Interferon-Alpha2b (Avi-005) In Healthy Subjects: An Open-Label, Single-Dose, Controlled Study., T B Patel, E Pequignot, S H Parker, M C Leavitt, H E Greenberg, Walter K. Kraft
Transgenic Avian-Derived Recombinant Human Interferon-Alpha2b (Avi-005) In Healthy Subjects: An Open-Label, Single-Dose, Controlled Study., T B Patel, E Pequignot, S H Parker, M C Leavitt, H E Greenberg, Walter K. Kraft
Department of Pharmacology and Experimental Therapeutics Faculty Papers
BACKGROUND/AIMS: This study characterized the safety and pharmacological properties of AVI-005, a novel glycosylated recombinant human interferon-alpha2b produced from the egg whites of chickens transfected with human cDNA.
METHODS: 18 healthy volunteers received single subcutaneous rising doses (0.5, 1.66 or 5 million international units, MIU) of AVI-005. A randomized parallel comparator group of 10 subjects received 5 MIU of unglycosylated IFN-alpha2b (Intron A). The pharmacokinetic parameters t1/2, tmax, Cmax, AUC0-24h, Vd, and clearance were compared between AVI-005 and unglycosylated IFN-alpa2b.
RESULTS: At equipotent doses, AVI-005 had a larger AUC0-24h than the control interferon. Pharmacodynamic markers ofneopterin and beta2-microglobulin for the …